Search the Newsreel

576,266 Shares in Adaptive Biotechnologies Corporation $ADPT Bought by Wasatch Advisors LP

Wasatch Advisors LP has acquired 576,266 shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) worth approximately $12.4 million, bringing institutional ownership in the company to 99.17%. Despite a reported wider-than-expected quarterly loss, Adaptive Biotechnologies saw a 21.5% year-over-year revenue increase. The stock is trading near its …

Earnings call transcript: Aditya Infotech Q1 2026 profit jumps, shares fall 5%

Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 3,000 shares under plan

Adaptive Biotechnologies' Chief Commercial Officer, MRD, Susan Bobulsky, sold 3,000 shares of common stock at $25.00 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on December 16, 2025. Following the sale, Bobulsky directly holds 396,989 …

XT Global Infotech Q1 Results: Consolidated net profit up 27% YoY to ₹3.89 crore

Adaptive Biotechnologies (ADPT) Stock Looks Fair On Cash Flow Yet Rich On Sales

Adaptive Biotechnologies (ADPT) stock appears fairly valued based on its discounted cash flow model, which places its intrinsic value close to its current share price. However, the stock looks expensive when evaluated using market multiples, particularly its P/S ratio, which is significantly higher than …

Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 3,000 Shares of Stock

Susan Bobulsky, an insider at Adaptive Biotechnologies (NASDAQ:ADPT), sold 3,000 shares of the company's stock for $75,000, reducing her total holdings by 0.75%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sale, institutional investors own a significant 99.17% of …

Adaptive Biotechnologies CCO Susan Bobulsky sells $75,000 in shares By Investing.com

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 3,000 shares of common stock totaling $75,000 at $25.00 per share on August 10, 2026. This transaction was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high …

Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Oncolytics Biotech (NASDAQ:ONCY) reported a quarterly loss of $0.08 per share, missing analysts' consensus estimate of a $0.05 loss by $0.03. Despite the earnings miss, the stock rose 0.5% to $0.82, and institutional investors have been increasing their holdings. Analysts currently rate the stock …

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology (VIR) reported significant financial improvements in Q2 2026, with $1.01 billion in cash and investments and $238.9 million in revenue, driven by a collaboration with Astellas. The company highlighted strong progress in its hepatitis delta program, with promising clinical trial results for …

ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources

Oncolytics Biotech Inc. (ONCY) reported a widened net loss of $9.4 million in Q2 2026, attributed to rising R&D and G&A expenses due to clinical trial expansion and increased stock-based compensation. While current cash is sufficient for near-term milestones, the company will require additional …

Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund

Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the …

Legend Biotech Shares Fall After Oppenheimer Downgrade

Legend Biotech's shares experienced a decline following an Oppenheimer downgrade from Outperform to Perform, citing potential pressures from competition and a CEO transition. Despite this, RBC maintained an Outperform rating for Legend Biotech, adjusting its price target slightly, due to positive outlooks on Carvykti …

Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028

Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate …

Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade

LEGN Downgraded by Oppenheimer -- Price Target Lowered to $40.00

Legend Biotech stock downgraded at Oppenheimer (LEGN:NASDAQ)

Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform following the resignation of its CEO, competitive pressures, and reduced M&A prospects. The analyst cited these factors as reasons for the downgrade. Legend Biotech's shares saw a decline on Wednesday after the announcement.

Astrotech forms advisory board for NASA lunar proposal

Astrotech Corporation has formed a Strategic Advisory Board consisting of four members to support its upcoming proposal for NASA's NextSTEP-3 Appendix A solicitation. The board will guide Astrotech on technology priorities, partnerships, and mission architectures related to lunar resource mining and autonomous operations. This …

China Conch Environment Sets August Board Meeting to Review Interim Results and Dividend

Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec SE announced a notification of major holdings, indicating that The Goldman Sachs Group, Inc. has acquired or disposed of shares with voting rights. As of August 6, 2026, Goldman Sachs holds a total of 13.71% of voting rights in Evotec SE, an increase …

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Oppenheimer downgrades Legend Biotech stock rating on M&A concerns

Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak …

Four advisors bring mining and lunar science experience to Astrotech

Astrotech (Nasdaq: ASTC) has formed a Strategic Advisory Board with four initial members: Dennis Wingo, Maj. Gen. (Ret.) John M. Olson, Ph.D., Clive R. Neal, Ph.D., and Gregory R. “Greg” Baiden, Ph.D. These advisors will provide technical and strategic guidance to support Astrotech's planned …

Green Fresh Biotechnology Narrows Interim Loss on Strong Carrageenan Sales

Acotec Issues Profit Warning After Halting U.S. Clinical Program

RBC Adjusts Price Target on Legend Biotech to $58 From $59, Maintains Outperform Rating

RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …

Global Market: European shares subdued as investors assess earnings, geopolitical risks ahead of US inflat

Legend Biotech Releases Q2 2026 Financial Results

Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …

Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50%

(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …

Legend Biotech (LEGN) Stock Rebounds As Profit Arrives But Carvykti Risk Persists

Legend Biotech (LEGN) Returned To Profit, Is The Stock Still Cheap?

PDS Biotechnology Halts PDS0101 Trial, Pivots to PDS0301 in Colorectal Cancer

PDS Biotechnology has announced the halt of its PDS0101 trial and internal investment, including the discontinuation of the Phase 3 VERSATILE-003 trial, to pivot its resources towards PDS0301. PDS0301, a tumor-targeted IL-12 immunocytokine, will now be the company's lead asset with a priority indication …

Alvotech (ALVO) to Announce Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is set to release its Q2 2026 earnings on Wednesday, August 19th, with analysts forecasting a loss of $0.0526 per share and revenue of $103.0 million. The company's previous quarter reported a loss of $0.09 per share and $105.9 million in revenue, …

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations - Caroline LeCates Paul TAKEAWAYS Worldwide Net …

Astrotech subsidiary plans lunar power utility network By Investing.com

Astrotech Corporation announced that its subsidiary, Lunar Power and Light Corporation (LP&L), plans to develop a commercial power-generation and distribution network on the Moon. This lunar electric utility would combine solar towers, battery storage, and transmission systems at a high-illumination lunar polar location. The …

INTELLIGENT PROTECTION MANAGEMENT ($IPM) Releases Q2 2026 Earnings

FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings

Fortress Biotech (NASDAQ: FBIO) is set to release its Q2 earnings report on August 12, 2026, with analysts forecasting an EPS of -$0.20 and revenue of $18.3 million. The stock is currently deemed 125.0% overvalued by GuruFocus' GF Value™ metric, trading at $2.61 against …